All

Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data
6 August 2026

Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data

Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced securing $60...

Read more
Another milestone for Reboat, a French pioneer in sailboat refurbishment: Seventure Partners takes a stake in the company to accelerate its growth
23 July 2026

Another milestone for Reboat, a French pioneer in sailboat refurbishment: Seventure Partners takes a stake in the company to accelerate its growth

Reboat announces the closing of a funding round led by Seventure Partners, alongside existing investors and business angels, including Charlotte Souleau, Managing Director for...

Read the press release
Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting
21 July 2026

Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies, today announced new positive interim data...

Read more
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
28 May 2026

Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies, today announced that the U.S. Food and...

Read more
vorteX-io raises €8.5 million to make hydrological data a driver of national sovereignty
27 May 2026

vorteX-io raises €8.5 million to make hydrological data a driver of national sovereignty

VorteX -io Raises €8.5 Million from Seventure Partners, Banque des Territoires, and Daphni to Turn Hydrological Data into a Lever for National Sovereignty and Address Global...

Read more
Microbiotica reports positive results for MB097 in advanced melanoma
18 May 2026

Microbiotica reports positive results for MB097 in advanced melanoma

Data suggests microbiome co-therapy may help overcome resistance to anti‑PD‑1 treatment.

Microbiotica has announced positive findings from its phase 1b MELODY‑1...

Read more
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
12 May 2026

Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-target in vivo immune therapies shown to induce a rapid, long-lasting and...

Read more
MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation
23 March 2026

MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more
Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
11 February 2026

Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive...

Read more